HUTCHMED Licenses KRAS-EGFR ATTC HMPL-A830 to GSK in Deal Worth Up to $1.295 Billion

September 3, 2026 5 Min Read

China-based biopharmaceutical company HUTCHMED has entered into an exclusive global licensing and development agreement with GSK for HMPL-A830, a potentially first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC), in a transaction that could be worth up to $1.295 billion before royalties.

Under the agreement announced on September 3, HUTCHMED will receive an upfront payment of $110 million and will be eligible for up to $1.185 billion in additional development, regulatory and commercial milestone payments, as well as tiered royalties on annual net sales of HMPL-A830.

The agreement gives a GSK subsidiary exclusive development and commercialization rights to HMPL-A830 worldwide outside Mainland China, Hong Kong, Macau and Taiwan. HUTCHMED will retain full development and commercialization rights across those Greater China markets. (Hutch Medical)

The transaction represents a significant endorsement of HUTCHMED’s emerging ATTC platform at a particularly early stage: HMPL-A830 remains preclinical and has yet to generate human clinical data.

A New Approach to Targeting KRAS

HMPL-A830 is designed to combine two established concepts in precision oncology in a single molecular construct. The candidate consists of a highly selective and potent small-molecule KRAS inhibitor payload conjugated to an anti-EGFR antibody.

HUTCHMED describes the technology as an Antibody-Targeted Therapy Conjugate, or ATTC. Although structurally related to the antibody-drug conjugate concept, HUTCHMED’s ATTC platform differs from conventional ADCs by coupling antibodies to targeted small-molecule inhibitors rather than traditional cytotoxic chemotherapy payloads. (Hutch Medical)

In HMPL-A830, the anti-EGFR antibody is intended to guide the conjugate toward EGFR-expressing tumor cells, where the KRAS inhibitor payload can exert its activity. At the same time, the construct is designed to interfere with both EGFR and KRAS signaling, providing two complementary mechanisms of tumor inhibition.

This strategy could potentially address two major challenges facing systemic KRAS inhibitors: normal-tissue toxicity and treatment resistance. By concentrating the KRAS inhibitor in EGFR-expressing tumors, HUTCHMED hopes to increase tumor-selective exposure while reducing systemic exposure to the payload.

The dual mechanism could also be particularly relevant because EGFR signaling can contribute to adaptive resistance following KRAS inhibition, especially in colorectal cancer. Preclinical evidence will now need to translate into human studies before those potential advantages can be established clinically.

Phase I Trial Expected to Begin in H2 2026

HUTCHMED will remain responsible for conducting the global Phase I development program for HMPL-A830, which is expected to begin in the second half of 2026.

The study is registered as NCT07718581 on ClinicalTrials.gov. Initial clinical development is expected to focus on patients with KRAS-altered colorectal cancer, pancreatic cancer and lung cancer.

These tumor types represent particularly important opportunities for KRAS-directed therapy. KRAS alterations are found in substantial proportions of colorectal cancer, lung adenocarcinoma and pancreatic ductal adenocarcinoma, but effective and durable targeted treatment remains challenging for many patients, particularly those carrying KRAS mutations not adequately addressed by currently available mutation-specific inhibitors. (www.pharmabiz.com)

Following the initial global Phase I program, GSK will assume responsibility for subsequent clinical development and commercialization outside Greater China.

Deal component	Details
Asset	HMPL-A830
Modality	KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC)
Antibody component	Anti-EGFR antibody
Payload	Potent small-molecule KRAS inhibitor
Licensor	HUTCHMED
Licensee	GSK subsidiary
GSK territory	Worldwide excluding Mainland China, Hong Kong, Macau and Taiwan
HUTCHMED territory	Greater China
Upfront payment	$110 million
Potential milestones	Up to $1.185 billion
Potential total payments	Up to $1.295 billion, excluding royalties
Royalties	Tiered royalties on annual net sales
Clinical status	Preclinical; Phase I planned
Initial indications	Colorectal, pancreatic and lung cancers
Phase I timing	Expected H2 2026
Clinical trial	NCT07718581

GSK Secures Option on Another HUTCHMED ATTC

The agreement extends beyond HMPL-A830.

As part of the transaction, GSK has also received a right of first negotiation (ROFN) on one earlier-stage ATTC candidate from HUTCHMED’s pipeline. (GlobeNewswire)

That provision suggests GSK’s interest extends beyond a single molecule to HUTCHMED’s broader conjugate technology.

HUTCHMED has been building an ATTC pipeline based on proprietary small-molecule inhibitor payloads. HMPL-A830 is the third drug candidate generated from the company’s novel payload platforms, following two candidates that have already entered clinical development. It is also the first candidate from these platforms to be licensed to a global pharmaceutical partner. (GlobeNewswire)

HUTCHMED’s other ATTC programs include HMPL-A251, a HER2-directed conjugate that entered Phase I/IIa development in late 2025, and HMPL-A580, an EGFR-directed conjugate carrying a PI3K/PIKK inhibitor payload that entered clinical development in 2026. (AllSci)

HUTCHMED Calls Deal a Milestone for Its ATTC Platform

Johnny Cheng, HUTCHMED’s Acting Chief Executive Officer and Chief Financial Officer, described the agreement as an important milestone for the company’s conjugate platform.

Cheng said HUTCHMED’s ATTCs combine antibodies with proprietary small-molecule inhibitor payloads to generate dual mechanisms of action, and highlighted HMPL-A830 as the third candidate generated from the novel payload platforms and the first to be partnered globally. (GlobeNewswire)

GSK also emphasized the potential of the dual-targeting approach.

Hesham Abdullah, GSK’s Senior Vice President and Global Head of Oncology R&D, said the company sees the dual KRAS-EGFR mechanism as having the potential to improve upon existing standards of care and described the transaction as part of GSK’s strategy to expand innovation within oncology. (GlobeNewswire)

Why the HMPL-A830 Deal Matters

The transaction is notable for several reasons.

First, the $110 million upfront payment for a preclinical asset represents a meaningful financial commitment by GSK before HMPL-A830 has produced human safety or efficacy data. The economics therefore provide an early external validation of both the molecule and HUTCHMED’s broader ATTC strategy.

Second, the program addresses one of the pharmaceutical industry’s most intensely pursued cancer targets. KRAS was historically considered “undruggable,” but the emergence of KRAS G12C inhibitors demonstrated that direct pharmacological targeting is possible. The field has subsequently expanded toward inhibitors covering other KRAS mutations as well as pan-KRAS and pan-RAS approaches.

However, resistance and tolerability remain important obstacles. Combining tumor-directed delivery with simultaneous EGFR blockade could offer a differentiated way of attacking those problems.

Third, the transaction gives HUTCHMED substantial downstream economics while allowing it to retain the entire Greater China opportunity. If HMPL-A830 succeeds, HUTCHMED could therefore benefit from milestone payments and royalties from GSK’s ex-China business while independently developing and commercializing the drug in China and neighboring retained markets.

The deal also highlights the growing role of Chinese biotech companies as sources of novel oncology technologies for multinational pharmaceutical companies. HUTCHMED shares listed in Hong Kong rose approximately 15% following the announcement, according to Reuters. (Reuters)

A High-Potential Program Still Facing an Important Clinical Test

Despite the size of the agreement, HMPL-A830 remains an early-stage program.

Its proposed advantages—including enhanced tumor-selective KRAS inhibition, dual EGFR/KRAS pathway suppression, improved tolerability and potentially greater durability—are based primarily on the molecule’s design and preclinical findings. Whether those characteristics translate into a meaningful therapeutic window in patients will be a central question for the upcoming Phase I study.

The first human trial will therefore be particularly important not only for HMPL-A830 but also for establishing the broader clinical potential of HUTCHMED’s ATTC platform.

For HUTCHMED, the GSK partnership nevertheless represents a major external validation of its next-generation conjugate strategy. For GSK, the deal provides access to a potentially first-in-class approach to KRAS-driven tumors at an early stage, while securing an additional opportunity through the ROFN on another HUTCHMED ATTC program.

If HMPL-A830 can demonstrate that antibody-guided delivery meaningfully expands the therapeutic window of potent KRAS inhibition while simultaneously suppressing EGFR-mediated signaling, the program could help establish ATTCs as a new category of precision oncology conjugates beyond conventional cytotoxic ADCs.